Abstract
SEVERAL studies have implicated the delayed hypersensitivity reaction in the body's response to cancer. Hughes and Lytton found that one cancer patient in four demonstrated a delayed cutaneous hypersensitivity response to an antigen consisting of small cytoplasmic particles obtained after ultrasonic disruption of their tumours1. There have been several studies of the ability of cancer patients to react to the antigens commonly used for delayed cutaneous hypersensitivity testing2–9; in general, while responsiveness was affected little, if at all, in patients with early cancer, it decreased as disease and debility progressed. The ability to develop contact sensitivity to dinitrochloro-benzene or dinitrofluoro-benzene is decreased in cancer patients, particularly those with advanced disease10,11. Such sensitivity has been shown to be related to prognosis12.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
